山东大学耳鼻喉眼学报 ›› 2010, Vol. 24 ›› Issue (6): 44-46.

• 论文 • 上一篇    下一篇

西妥昔单抗联合术后同步放化疗治疗晚期复发性头颈癌的初步观察

於子卫,董频,庞正   

  1. 上海交通大学附属第一人民医院耳鼻咽喉-头颈外科,上海 200080
  • 收稿日期:2010-09-04 修回日期:2010-10-26 发布日期:2010-12-16
  • 作者简介:於子卫(1967- ),男,主任医师,主要从事头颈部肿瘤的手术和临床研究。 Email: david545yu@yahoo.com

Clinical study of cetuximab combined with post-operative concurrent  chemo-radiotherapy on recurrent advanced squamous cell-carcinoma of the head and neck

YU Zi-wei, DONG Pin, PANG Zheng   

  1. Department of Otolaryngology, Head and Neck Surgery, Shanghai Jiao Tong University Affiliated First People′s Hospital, Shanghai 200080, China
  • Received:2010-09-04 Revised:2010-10-26 Published:2010-12-16

摘要:

目的    评价西妥昔单抗联合术后同步放化疗治疗晚期复发性喉癌及下咽癌患者的近期疗效和不良反应。方法    晚期复发性头颈癌患者6例,其中喉复发癌2例,下咽复发癌1例,下咽癌伴肺转移1例,气管造瘘口复发癌2例。分别予以手术治疗后3周,西妥昔单抗与同步放化疗,用法:西妥昔单抗第1周初始剂量为400mg/m2,以后每周维持剂量为250mg/m2,共3周。所有患者均采用直线加速器放疗,常规分割调强放疗,总剂量60Gy,6周完成。在放疗的同时给予化疗,方案是:DDP 80mg/m2/d1,5Fu 800mg/m2,120h持续化疗泵静滴。化疗1次/3周,共3次。结果     所有患者均顺利完成治疗计划。西妥昔单抗主要不良反应为皮疹、口腔炎、疲乏等。中位随访10个月,病例均存活且肿瘤无进展,未发生远处转移。结论    西妥昔单抗联合术后同步放化疗治疗晚期复发性头颈癌安全有效,治疗计划顺利进行,尚需进行进一步临床试验研究。

关键词: 西妥昔单抗;复发性头颈癌;同步放化疗;疗效;毒性

Abstract:

Objective    To evaluate the clinical efficacy of cetuximab combined with concurrent chemo-radiotherapy on recurrent advanced squamous cell carcinoma of the head and neck. Methods    6 patients with recurrent advanced head and neck carcinoma,including 2 larnyngeal carcinoma, 1 hypopharyngeal carcinoma, 1 hypopharyngeal carcinoma with lung metastasis and 2 stomal recurrence, were treated with cetuximab combined with postoperative radiotherapy and chemotherapy. Cetuximab was administered at an initial dose of 400mg/m2 in the first week followed by weekly injection of 250mg/m2. All the patients received a total dose of 60Gyradiation(2Gy per fraction, 5 fractions per week ) and concurrent chemotherapy(cisplatin 80mg/m2 d1 and 5-Fu 800mg/m2 per week with 120 hour continuous intravenous injection). Results    All the patients completed the designated treatment. The primary side effects consisted of acne-like rash, stomatitis, and asthenia. All patients survived after 10 months of median followup time, and no progression and metastasis occurred. Conclusion     Cetuximab combined with postoperative concurrent chemoradiotherapy is efficient and safe for the management of recurrent advanced carcinoma of head and neck, however, a further largescale clinical trial is necessary.

Key words: Cetuximab ; Recurrent carcinoma of head and neck ; Concurrent chemoradiotherapy ; Efficacy ; Toxicities

中图分类号: 

  • R739.91
[1] 林振华,莫宋平,陈振清,杨礼明,符士楠,彭峰. 成人颈部淋巴管瘤的手术治疗[J]. 山东大学耳鼻喉眼学报, 2012, 26(3): 59-60.
[2] 渠晨晖1,寿建伟1,郭艳1, 王丽杰2,余晓旭3. 超声引导下针吸细胞学检查在头颈肿瘤围手术期的临床应用价值评估[J]. 山东大学耳鼻喉眼学报, 2012, 26(2): 32-34.
[3] 祝江才,陈歆维,王菲,王国良,董频. 颈部神经鞘瘤的诊断与手术治疗6例[J]. 山东大学耳鼻喉眼学报, 2011, 25(3): 9-11.
[4] 叶婷1,马超2,潘新良1. 下咽癌瘤内淋巴管生成及颈淋巴转移关系的研究[J]. 山东大学耳鼻喉眼学报, 2011, 25(1): 24-.
[5] 赵芹芳1,李万海1,郭庆生2. 头颈部淋巴管瘤超声检查3例[J]. 山东大学耳鼻喉眼学报, 2010, 24(4): 16-16.
[6] 吕佳宝综述,邱连升审校. p27kip1、Skp2与头颈部肿瘤关系的研究进展[J]. 山东大学耳鼻喉眼学报, 2009, 23(5): 17-20.
[7] 刘斌 江育玲 任基浩. 颈交感神经鞘瘤CT表现与手术对照研究[J]. 山东大学耳鼻喉眼学报, 2009, 23(4): 18-20.
[8] 管杰1综述,刘大昱2审阅. 颈部囊性水瘤的诊断与治疗进展[J]. 山东大学耳鼻喉眼学报, 2009, 23(6): 24-28.
[9] 钱晔,雷大鹏,金童,刘大昱,许风雷,潘新良. Slit2在喉咽鳞癌中的表达及其与LVD关系的研究[J]. 山东大学耳鼻喉眼学报, 2012, 26(5): 12-15.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!